Ligand Pharma (LGND) Tops Q3 EPS by 8c
Tweet
Share
E-mailGet Alerts LGND Hot Sheet
Price: $290.07 +2.32%
Revenue Growth %: -32.2%
Financial Fact:
Loss from operations: 5.47M
Today's EPS Names:
ALZN, ASPU, OCCI, More
Revenue Growth %: -32.2%
Financial Fact:
Loss from operations: 5.47M
Today's EPS Names:
ALZN, ASPU, OCCI, More
Join SI Premium – FREE
Ligand Pharma (NASDAQ: LGND) reported Q3 EPS of $0.69, $0.08 better than the analyst estimate of $0.61. Revenue for the quarter came in at $33.38 million versus the consensus estimate of $30.91 million.
GUIDANCE:
Ligand Pharma sees FY2017 revenue of $134-136 million, versus the consensus of $134.5 million.
For earnings history and earnings-related data on Ligand Pharma (LGND) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Jefferies Starts Oversea-Chinese Banking Corp Ltd (OCBC:SP) (OVCHF) at Hold
- UBS Downgrades Buzzi Unicem SpA (BZU:IM) (BZZUY) to Sell
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
